Medpace slips after hours despite Q3 beat, raised guidance

Medpace reported Q3 EPS and sales above consensus, new orders and backlog also topped forecasts. Full-year guidance came in above analyst estimates. Despite the beat, shares fell in after-hours trading as the stock had already rallied 6.4% during the regular session, suggesting high expectations were priced in.